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SedationAbstract Background: Endotracheal tube tolerance is a major concern in patients who require
postoperative retention of endotracheal tube following major head and neck cancer surgeries. This
study investigates the role of Dexmedetomidine for endotracheal tube tolerance, opioid sparing
effect and sedation.
Methods: Prospective randomised double blind control study. Sixty-four patients scheduled for
head and neck surgery lasting longer than 2 h who require post operative endotracheal tube reten-
tion were randomly allocated into two groups of 32 each. The Dexmedetomidine group (Group D,
n= 32) received Dexmedetomidine 1 lg kg1 diluted to 10 ml, i.v. over 10 min prior to reversal and
thereafter 0.2 lg kg1 h1 i.v. infusion till extubation while the control group (Group P, n= 32)
received 10 ml normal saline i.v. over 10 min prior to reversal and volume-matched normal saline
infusion as placebo till extubation. The two groups of patients were compared for haemodynamic
changes during administration of the bolus drug, after reversal and in the ICU. The quality of endo-
tracheal tube tolerance, analgesic requirement and sedation were also compared between the two
groups in the ICU.
Results: Group D tolerated the endotracheal tube better than Group P based on cough (p< 0.01)
and nurses’ judgement (p< 0.01). Group D showed 72% decrease in morphine requirement
(p< 0.05), experienced arousable sedation (p< 0.05) and the vital parameters were better pre-
served (p< 0.05) than Group P.
Conclusions: Patients receiving Dexmedetomidine tolerated the endotracheal tube better, required
lesser morphine, were adequately sedated, arousable, stable haemodynamics and lacked respiratory
depression.
 2015 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.angady,
.
Figure 1 CONSORT statement flow diagram – study design.
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Postoperative airway obstruction is a relatively common
complication after anaesthesia for head and neck surgery [1].
Prolonged surgery, tissue oedema and possible post operative
bleeding can result in airway compromise.
In a patient undergoing lengthy head and neck surgical
procedure, the trachea may remain intubated and the patient
sedated overnight in the intensive care unit [2]. The goal is to
prevent pain, provide sedation and limit reflex responses to
the endotracheal tube. Tolerance of the endotracheal tube is
facilitated by intravenous hypnotics (e.g., propofol) and
opioids (e.g., fentanyl, morphine) in low doses.
The danger of respiratory depression with these drugs often
necessitates their discontinuation before extubation leading to
patient anxiety and discomfort. The possibility of continuing
sedation throughout extubation without significant respiratory
impairment makes Dexmedetomidine a favourable option
[3,4].
1.1. Aims and objectives
Major head and neck cancer surgery patients require to retain
the endotracheal tube postoperatively for 16–20 h.
Endotracheal tube tolerance is a major concern in this context.
Dexmedetomidine has been proved to be effective for its
opioid sparing effect, rousable sedation and lack of respiratory
depression with haemodynamic stability [3–8]. This study
investigates whether Dexmedetomidine will be a better alterna-
tive than routinely used drugs for alleviating discomfort and
pain due to endotracheal tube maintaining high degree of
patient rousability.
Besides the primary objective, the study also investigates
the effect of Dexmedetomidine on the haemodynamic
variables and the overall ease of patient management.
2. Materials and methods
The study was approved by the institutional review board and
ethics committee (Ref:HEC.No.29/2010).
A prospective randomised double blind control study was
initiated. The study population included 64 Patients, ASA I
and II in the age group 20–70 yrs scheduled for elective head
and neck surgery lasting longer than two hours who need to
retain the endotracheal tube in the post operative period. Of
these, 32 patients received Dexmedetomidine (Group D) and
32 patients received placebo saline (Group P) (see Fig. 1).
Written informed consent was taken from each patient.
2.1. Inclusion criteria
ASA I and ASA II patients in the age group 20–70 yrs
scheduled for elective head and neck surgery lasting longer
than 2 h who require to retain the endotracheal tube in the
post operative period were included in the study.
2.2. Exclusion criteria
Patients below 20 yrs and above 70 yrs of age, ASA grade
more than II, patient with arrhythmias, patient with congestiveheart failure, patient with dementia, patient with heart block
and pregnant patients were excluded.
2.3. Premedication
All patients were kept nil orally from 12 midnight prior to day
of surgery. All patients were premedicated with Tab.
Alprazolam 0.25 mg – 0.5 mg, Tab. Pantoprazole 40 mg and
Tab. Domperidone 10 mg orally previous night and 6 am on
the day of surgery.
2.4. Anaesthesia technique
On arrival at the OT, baseline heart rate, NIBP, SPO2 values
were recorded. The patients were premedicated with Inj.
Midazolam 1 mg i.v., Inj. Glycopyrrolate 0.2 mg i.v. and Inj.
Fentanyl 2 lg kg1 i.v. Two drops of Xylometazoline nasal
drops 0.1%, were instilled into each nostril.
General anaesthesia was induced with propofol
2–2.5 mg kg1 i.v. Inj. Vecuronium 0.1 mg kg1 was given
i.v. to facilitate nasal endotracheal intubation using 7.5 mm
cuffed tube for males and 7 mm cuffed tube for females. The
endotracheal tube was secured after confirming the position of
the tube by auscultation and ETCO2. Following placement of
the endotracheal tube, anaesthesia was maintained with 66%
Nitrous oxide in oxygen 2:1 ratio at fresh gas flow of 1.5 litres/
min and Isoflurane 0.5 – 2% using closed circuit. Inj. Vecuro-
nium was given in 1 mg increments to maintain neuromuscular
blockade. No additional opioid was given after induction.
Intraoperatively, Inj. Diclofenac 75 mg was given as slow
intravenous infusion. Inj. Ondansetron 4 mg intravenous was
given as antiemetic. Nitroglycerin i.v. infusion was used in
titrated doses to maintain mean arterial pressure of 60 mmHg.
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ECG, NIBP, SPO2, ETCO2 were monitored throughout the
procedure.
Ten minutes prior to administration of reversal, the study
drug and placebo were given according to group allocation as
per computer generated random numbers in a double blinded
manner. Group D received a bolus of Dexmedetomidine
1 lg kg1 diluted to 10 ml with normal saline i.v. over 10 min.
GroupP received a bolus of 10 ml normal saline i.v. over 10 min.
Heart rate and B.P were recorded at the start of the bolus
drug injection and at 1 min, 3 min, 5 min, and 10 min after
administration of the drug. At the end of surgery, neuromuscu-
lar block was antagonised with Neostigmine 0.05 mg kg1 i.v.
and glycopyrrolate 0.01 mg kg1 i.v. Subsequently 1 min,
3 min, 5 min, 10 min and 15 min after reversal, the heart rate
and blood pressure were recorded. Coughing after reversal
was also noted. Morphine 0.05 – 0.1 mg kg1 i.v. bolus was
given for intolerance to endotracheal tube, pain and agitation.
Ephedrine 6–12 mg i.v. bolus was given for hypotension [de-
crease in systolic pressure >20% from baseline]. Atropine
0.6 mg i.v. bolus was given for bradycardia. [Heart rate <45/
min.] The patient was then shifted to the post surgical intensive
care unit with the nasal endotracheal tube in situ.
On arrival at ICU, Dexmedetomidine i.v. infusion at
0.2 lg kg1 h1 or volume matched normal saline i.v. infusion
was started as per group allocation and continued till extuba-
tion. In the ICU, the nurses were blinded to the intravenous
drug infused. Heart rate, NIBP and SpO2 were recorded every
15 min for the 1st hour, then hourly for 5 h and subsequently
every 2 h till extubation. The sedation level, coughing,
morphine requirement and endotracheal tube tolerance
of the patients, as judged by the nurses, were also recorded.
Inj. Morphine 0.05 – 0.1 mg kg1 i.v. bolus was given for
intolerance to endotracheal tube, pain and agitation. Ephedrine
6–12 mg i.v. bolus was given for hypotension [decrease in sys-
tolic pressure >20% from baseline]. Atropine 0.6 mg i.v. bolus
was given for bradycardia. [Heart rate <45/min.]
2.5. Statistical analysis
The minimum group size of 64 was calculated in order to
achieve a study power of 80% with a error of 5%. The data
was presented as mean (SD). Statistical analysis was done by
software SPSS (Statistical package for social sciences) version
11.0. Statistical analysis was performed using appropriate
application of statistical tools-Chi square test, independent ‘t’
test and Fisher’s exact test.P< 0.05 was considered significant.
3. Results
The two groups were comparable in patient characteristics,
baseline vital signs and duration of surgery [Table 1].
Prior to administration of the reversal drug, as the bolus
drug was administered the heart rate between the two groups
was comparable till 3 min and thereafter there was a significant
decrease in heart rate in patients of group D compared to
group P (p< 0.05). The systolic blood pressure was compara-
ble at all times, but at 10 min, patients of group D had
significantly lower systolic blood pressure compared to group
P (p< 0.01).After administration of the reversal drug, the patients in
group D had significantly lower heart rate (p< 0.01), systolic
blood pressure (p< 0.01) and diastolic blood pressure up to
15 min compared to group P. There was significantly lesser
coughing at 1 min and 3 min in group D compared to group
P (p< 0.05). The frequency of bolus morphine i.v. adminis-
tered was significantly lesser in the patients of group D
compared to group P (p< 0.01).
In the ICU, as the patients received drug infusion, the
patients in group D had significantly lower heart rate
compared to group P (p< 0.01) [Fig. 2]. The patients in group
D had lower systolic and diastolic BP compared to group P
[Fig. 3].
Patients in group D maintained respiratory rate better than
group P (p< 0.05). Group D showed better oxygen saturation
than group P (p< 0.05).
The frequency and dose of morphine requirement in the
ICU was significantly lesser in group D compared to group
P (p< 0.05) [Fig. 4]. Coughing was significantly lesser
(p< 0.01) and milder in Group D than group P especially at
45 min, 3 h, 5 h, 12–18 h (p< 0.05) in the ICU [Fig. 5].
The patients in group D were better sedated and easily
arousable in the ICU compared to group P, which was
statistically significant (p< 0.05) at 15 min, 30 min and 18 h,
(p< 0.01) at 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 14 h and 16 h.
The nurses judged that patients in group D tolerated the
endotracheal tube better than group P in the ICU.
(p< 0.01) [Fig. 6].4. Discussion
We conducted this prospective randomised study to determine
the role of Dexmedetomidine as a better alternative than rou-
tinely used drugs for endotracheal tube tolerance, analgesia
and sedation.
Dexmedetomidine is a highly selective a2 agonist that
possesses hypnotic, sedative, anxiolytic, sympatholytic, anal-
gesic and anaesthetic sparing effects without causing signifi-
cant respiratory depression [9–12]. It causes dose-dependent
decrease in arterial blood pressure and heart rate associated
with decrease in plasma catecholamines [13].
As the bolus drug was administered, the patients in Group
D had a significantly lower heart rate than Group P from
3 min onwards. None of the patients in Group D required
intervention for bradycardia. Patients in Group D had a lower
systolic BP at all times and the difference was statistically
significant at 10 min. Four patients in Group D required
intervention for hypotension.
Following administration of the reversal drug, there was a
significant decrease in heart rate in the patients of Group D
at all times for 15 min compared to the Group P (p< 0.01).
The systolic BP after reversal was significantly lower in Group
D compared to Group P at all times for 15 min (p< 0.01).
There was significantly lesser coughing experienced at 1 min
(p< 0.01) and 3 min (p< 0.05) by patients of Group D. Mor-
phine bolus requirement as rescue opioid was less in Group D
at all times till 10 min after reversal. This difference was most
significant at 1 min (p< 0.01) when only 9.4% of patients in
Group D required morphine bolus compared to 40.6% of
patients in Group P.
Table 1 Patient demographics and baseline cardiorespiratory
parameters of Group D (Dexmedetomidine) and Group P
(Control).
Group D Group P p
Weight 61.7 ± 13.2 58.1 ± 11.4 0.194
Baseline pulse rate 83.3 ± 12.2 84.7 ± 14 0.844
Baseline SBP 124.5 ± 10.9 130.4 ± 17.1 0.232
Baseline DBP 76.9 ± 7.4 79.3 ± 8.4 0.420
Mean BP 92.7 ± 7.2 96.4 ± 10.4 0.025
Baseline SpO2 98.7 ± 1.2 98.9 ± 0.8 0.606
Baseline respiratory rate 14.9 ± 1.3 14.7 ± 1.3 0.606
Duration of procedure 4 ± 1.3 3.6 ± 1.2 0.376
AGE 46.3 ± 13.3 49.8 ± 15 0.067
Male: Female 62.5: 37.5 56.3: 43.8 0.611
ASA Grade I: II 18.8: 81.3 18.8: 81.3 1.000
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was lower than the control group which was highly significant
at 15 min through 1 h (p< 0.01) and significant (p< 0.05) at
most times through 20 h till extubation [Fig. 2]. The patients of
Group D had lower systolic and diastolic BP than Group P.
The difference between the groups was significant at 15 min
after the start of the infusion through the 20 h till extubation
(p< 0.01) [Fig. 3]. The patients of Group D maintained
normal respiratory rate and had higher oxygen saturation
(p< 0.01) than Group P and the difference was significant
at most times through 20 h. The mean total morphine require-
ment in Group D was 72% lesser than Group P [Fig. 4]. There
was significantly lesser coughing (p< 0.01) and less intense
cough in patients of Group D [Fig. 5]. The patients of Group
D were adequately sedated compared to Group P and this was
significant throughout. None of the patients were sedated to
the point of non arousal. Group D tolerated the endotracheal
tube better than Group P as judged by the nurses [Fig. 6].Figure 2 Comparison of heart rate in Group D (Dexmedeto-
midine) and Group P (Control) in the ICU.Following bolus drug administration, heart rate changes in
our study were similar to the study conducted by Jain et al.
[14]. The trials by Martin et al. [4], Guler et al. [15] showed
bradycardia of which few required intervention. Study by
Guler et al. [15] found a significant decrease in systolic BP at
3 min and 5 min after administration of Dexmedetomidine,
whereas no significant change was noted in systolic BP in the
study done by Jain et al. [14]. In our study, four patients in
Group D required intervention for hypotension.
Following reversal, our results are in accordance with stud-
ies by Martin et al. [4] but differs from previous studies [14,15]
where increase in heart rate was noted in both groups, but to a
lesser extent in the group that received Dexmedetomidine. The
lower systolic BP noted in Group D was consistent with trials
by Martin et al. [4]. Trial by Jain et al. [14] showed no change
in systolic BP in the Dexmedetomidine group and a mild
increase in the control group whereas trial by Guler et al.
[15] stated increase in systolic BP in both groups but to a lesser
extent in the Dexmedetomidine group. The increase in heart
rate and BP in the Dexmedetomidine group in previous studies
[14,15] may be due to the fact that patients underwent extuba-
tion whereas in our study the patients retained the endotra-
cheal tube. Extubation like intubation is an acute stimulus
associated with haemodynamic changes.
In the ICU, our observations of heart rate and B.P. were in
accordance with trials by Martin et al. [4], the only difference
being a higher incidence of bradycardia and hypotension in
their study. Blood pressure and heart rate reductions in the
patients receiving Dexmedetomidine were predictable for an
alpha2 adrenoreceptor agonist and stayed within the clinically
acceptable range for most of the patients. Villella and
Nascimento [16] observed that Dexmedetomidine infusion in
the postoperative period improves haemodynamic stability.
Patients who are at high risk of postoperative cardiovascu-
lar complications may benefit from Dexmedetomidine’s
predictable reductions in blood pressure, heart rate [9,17],Figure 3 Comparison of systolic BP and diastolic BP in Group
D (Dexmedetomidine) and Group P (Control) in the ICU.
Figure 4 Comparison of morphine requirement in Group D
(Dexmedetomidine) and Group P (Control) in the ICU.
Figure 5 Comparison of the percentage of patients in Group D
(Dexmedetomidine) and Group P (Control) experiencing cough at
different time interval in the ICU.
Figure 6 Comparison of the quality of endotracheal
tube tolerance in Group D (Dexmedetomidine) and Group P
(Control) in the ICU. Mean value 1–2 (Excellent–Good), 2–3
(Good–Moderate).
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by Talke and Mangano [19], reducing the heart rate and blood
pressure appeared to reduce the risk of perioperative ischaemia
and hypoxia. Studies by Mangano [20], the MSPI Europe
Research Group [21], and Oliver et al. [22] demonstrated that
perioperative therapy with alpha2 – adrenoreceptor agonists
decreased both the incidence of myocardial infarction and
mortality in the perioperative period. Data by Mangano
et al. [23] supported by Raby et al. [24] demonstrated that it
was the reduction of heart rate and not beta-adrenergic block-
ade per se, that was beneficial. Lawrence et al. [25] demon-
strated that the sympatholytic effect of Dexmedetomidine
decreased heart rate and contractility, increased coronary
blood supply to the left ventricle by prolonged diastole, and
decreased myocardial oxygen consumption.
The trials conducted by Venn et al. [26] show that
Dexmedetomidine appears to have no clinically important
adverse effects on respiratory rate and gas exchange when used
in spontaneously breathing ICU patients after surgery. Unlike
our study, Martin et al. [4] found no significant difference in
oxygen saturation (p= 0.846) and mean respiratory rate
between the two groups.
Our finding of reduced morphine requirement in Group D
correlates with findings by Martin et al. [4]. The studies by Alex
Bekker et al. [27] and Hassan et al. [28] support our finding of
opioid sparing effect of Dexmedetomidine. The analgesic spar-
ing effect of Dexmedetomidine has been demonstrated in ear-
lier studies [29–31]. Our results of endotracheal tube tolerance
are consistent with the study by Martin et al. [4].
The major limitations of the study are the absence of a pain
scale and the subjective assessment of endotracheal tube
tolerance.5. Conclusion
Dexmedetomidine is efficacious for postoperative endotracheal
tube tolerance. It has opioid sparing effect and can be used as a
sole sedative agent without the danger of respiratory depres-
sion. Dexmedetomidine prevents postoperative hypertension
and tachycardia and promotes easier management of patients
with endotracheal tube in the surgical ICU. Although close
monitoring is needed to detect hypotension and/or bradycar-
dia Dexmedetomidine has a useful role in the multimodal
approach to management of post surgical patients.Author’s contribution
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